Cardiovascular

FDA approves Impavido to treat leishmaniasis

On March 19, the U.S. Food and Drug Administration (FDA) approved Impavido (miltefosine) to treat a tropical disease called leishmaniasis. Read more.


Related Articles:

Leave a Reply

You have to agree to the comment policy.

 

Test Your Nursing Knowledge

Answer this interactive quiz to be entered to win a gift card.

  • This field is for validation purposes and should be left unchanged.

Insights Blog

Today’s News in Nursing

Shares